Drummond E-Wen McCulloch , Juan Pablo Lopez , Christina Dalla , Eero Castrén , David Erritzoe , Vibe G. Frokjaer , Johan Lundberg , Katrin H. Preller , Patrick MacDonald Fisher , Gitte Moos Knudsen
{"title":"迷幻药医学化的知识空白：临床前和神经成像机制","authors":"Drummond E-Wen McCulloch , Juan Pablo Lopez , Christina Dalla , Eero Castrén , David Erritzoe , Vibe G. Frokjaer , Johan Lundberg , Katrin H. Preller , Patrick MacDonald Fisher , Gitte Moos Knudsen","doi":"10.1016/j.nsa.2023.103929","DOIUrl":null,"url":null,"abstract":"<div><p>Classical psychedelic drugs, e.g., psilocybin and LSD, stimulate the serotonin 2A receptor (5-HT2AR) and have recently been intensely investigated for their clinical effects in various brain disorders. At the ECNP “New Frontiers meeting” in March 2023, scientific experts in psychedelics met to identify key knowledge gaps in the mechanism of action of psychedelics as investigated using preclinical models and clinical neuroimaging. Key themes included the development of appropriate behavioural models for measuring acute and persisting effects, dose optimisation, molecular mechanisms of action, sex differences, and the acute and persisting effects of psychedelics on neurotransmitter release and functional brain activity.</p></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 103929"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772408523029113/pdfft?md5=dc5df6034a6f3bde579a61c7b1ac0167&pid=1-s2.0-S2772408523029113-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms\",\"authors\":\"Drummond E-Wen McCulloch , Juan Pablo Lopez , Christina Dalla , Eero Castrén , David Erritzoe , Vibe G. Frokjaer , Johan Lundberg , Katrin H. Preller , Patrick MacDonald Fisher , Gitte Moos Knudsen\",\"doi\":\"10.1016/j.nsa.2023.103929\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Classical psychedelic drugs, e.g., psilocybin and LSD, stimulate the serotonin 2A receptor (5-HT2AR) and have recently been intensely investigated for their clinical effects in various brain disorders. At the ECNP “New Frontiers meeting” in March 2023, scientific experts in psychedelics met to identify key knowledge gaps in the mechanism of action of psychedelics as investigated using preclinical models and clinical neuroimaging. Key themes included the development of appropriate behavioural models for measuring acute and persisting effects, dose optimisation, molecular mechanisms of action, sex differences, and the acute and persisting effects of psychedelics on neurotransmitter release and functional brain activity.</p></div>\",\"PeriodicalId\":100952,\"journal\":{\"name\":\"Neuroscience Applied\",\"volume\":\"3 \",\"pages\":\"Article 103929\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772408523029113/pdfft?md5=dc5df6034a6f3bde579a61c7b1ac0167&pid=1-s2.0-S2772408523029113-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroscience Applied\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772408523029113\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience Applied","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772408523029113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
Classical psychedelic drugs, e.g., psilocybin and LSD, stimulate the serotonin 2A receptor (5-HT2AR) and have recently been intensely investigated for their clinical effects in various brain disorders. At the ECNP “New Frontiers meeting” in March 2023, scientific experts in psychedelics met to identify key knowledge gaps in the mechanism of action of psychedelics as investigated using preclinical models and clinical neuroimaging. Key themes included the development of appropriate behavioural models for measuring acute and persisting effects, dose optimisation, molecular mechanisms of action, sex differences, and the acute and persisting effects of psychedelics on neurotransmitter release and functional brain activity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
